Skip to main content

Table 1 Demographics

From: Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma

ParametersNo. of Cases (%)
Age
 Less than 67 yrs212 (43.4)
 More than 67 yrs277 (56.6)
Sex
 Male294 (60.1)
 Female195 (39.9)
Size
 Less than 4.9 cm256 (524)
 More than 4.9 cm233 (47.6)
Location
 Ascending110 (22.5)
 Transverse to sigmoid242 (49.5)
 Rectum122 (24.9)
 NAa15 (3.1)
Histologic type
 Intestinal type480 (98.2)
 Mucinous type9 (1.8)
Differentiation
 Well52 (10.6)
 Moderately410 (83.8)
 Poorly18 (3.7)
 NAa9 (1.8)
Lymphovascular invasion
 Absence327 (66.9)
 Presence145 (29.7)
 NAa17 (3.5)
Perineural invasion
 Absence299 (61.1)
 Presence52 (10.6)
 NAa138 (28.2)
pT category
 pT1–281 (16.6)
 pT3354 (72.4)
 pT454 (11.0)
Lymph node metastasis
 Absence276 (56.4)
 Presence213 (43.6)
Stage
 I65 (13.3)
 II206 (42.1)
 III196 (40.1)
 IV22 (4.5)
Deficient mismatch repair
Colon
 Absence335 (91.0)
 Presence33 (9.0)
Rectum
 Absence113 (93.4)
 Presence8 (6.6)
Chemo-or Radiotherapy
 Only surgical resection179 (36.6)
 Adjuvant chemotherapy267 (54.6)
 Neoadjuvant chemoradiotherapy14 (2.9)
 Adjuvant chemoradiotherapy29 (5.9)
Local recurrence
 Negative304 (61.8)
 Positive185 (37.8)
Disease-specific death
 Alive291 (59.7)
 Dead197 (40.3)
PD-1 expression
 Low304 (62.2)
 High177 (36.4)
 NAa8 (1.6)
CD8 expression
 Low305 (62.4)
 High173 (35.4)
 NAa11 (2.2)
PD-L1 expression
 Negative302 (61.8)
 Positive179 (36.6)
 NAa8 (1.6)
Tumour microenvironment immune type
 Type I (PD-L1+/CD8H)90 (18.4)
 Type IV (PD-L1−/CD8H)83 (17.0)
 Type III (PD-L1+/CD8L)87 (17.8)
 Type II (PD-L1−/CD8L)218 (44.6)
 NAa11 (2.2)
  1. aNot assessable due to no clinical information, cautery artifact, fragmentation, or incorrect orientation of tumour tissues